Canada, Qatar, and South Korea Approve PharmaMar’s Treatment Commercialization
The global regulatory footprint for Zepzelca continues to expand as health authorities in Canada, Qatar, and South Korea officially approve the commercialization of the oncology treatment for small cell lung cancer. Developed by the Spanish biopharmaceutical firm PharmaMar, the targeted therapy provides a critical new option for adult patients facing limited therapeutic alternatives following initial … Read more